Undisclosed

Santhera Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome

Lead Product(s): Lonodelestat

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: CSHL

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 27, 2020

Details:

Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.

Light Chain Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

Lead Product(s): NI-0101

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Edesa Biotech

Deal Size: $372.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 20, 2020

Details:

The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.

Novellus

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19

Lead Product(s): Mesenchymal stem cells

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Citius Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 01, 2020

Details:

Citius signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome from a subsidiary of Novellus.

InflaRx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19

Lead Product(s): Ifx-1

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands.

Kiniksa Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab

Lead Product(s): Mavrilimumab

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned.

Partner Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine

Lead Product(s): Sargramostim

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

Leukine can be used for treating COVID-19 induced acute hypoxic respiratory failure and ARDS in a nebulized form for immediate inhalation or by intravenous injection.

Ampio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion

Lead Product(s): Ampion

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

Ampio is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 induced ADRS.

Roivant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody for COVID-19 Treatment

Lead Product(s): Gimsilumab

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

Roivant will prioritize trials of gimsilumab in patients with COVID-19 instead of a Phase 2 trial in a separate disease area which had been previously planned.

University of Pittsburgh

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

University City Science Center inks partnership with CSL Behring

Lead Product(s): Chemokine-derived antifibrotic peptides

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: CSL Behring

Deal Size: $0.2 million Upfront Cash: Undisclosed

Deal Type: Partnership February 13, 2020

Details:

Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative.

Bioxytran

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Bioxytran Seeking Partners for Late Stage Treatment of Coronavirus

Lead Product(s): BXT-25

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 05, 2020

Details:

Bioxytran seeks to explore collaborations with international drug makers to treat patients at the end stage of Acute Respiratory Distress Syndrome affected with Wuhan Coronavirus.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Santhera Pharmaceuticals

Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome

Light Chain Bioscience

Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

Novellus

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19

InflaRx

03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19

Kiniksa Pharmaceuticals

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab

Partner Therapeutics

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine

Ampio Pharmaceuticals

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion

Roivant Sciences

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody for COVID-19 Treatment

University of Pittsburgh

University City Science Center inks partnership with CSL Behring

Bioxytran

Bioxytran Seeking Partners for Late Stage Treatment of Coronavirus